共 50 条
COVID-19 vaccines
被引:190
|作者:
Ndwandwe, Duduzile
[1
]
Wiysonge, Charles S.
[1
,2
,3
]
机构:
[1] South African Med Res Council, Cochrane South Africa, ZA-7501 Cape Town, South Africa
[2] Stellenbosch Univ, Fac Med & Hlth Sci, Div Epidemiol & Biostat, ZA-7505 Cape Town, South Africa
[3] Univ Cape Town, Fac Hlth Sci, Sch Publ Hlth & Family Med, ZA-7925 Cape Town, South Africa
基金:
英国医学研究理事会;
关键词:
D O I:
10.1016/j.coi.2021.07.003
中图分类号:
R392 [医学免疫学];
Q939.91 [免疫学];
学科分类号:
100102 ;
摘要:
COVID-19 is a pandemic of unprecedented proportions in recent human history. Less than 18 months since the onset of the pandemic, there are close to two hundred million confirmed cases and four million deaths worldwide. There have also been massive efforts geared towards finding safe and effective vaccines. By July 2021 there were 184 COVID-19 vaccine candidates in pre-clinical development, 105 in clinical development, and 18 vaccines approved for emergency use by at least one regulatory authority. These vaccines include whole virus live attenuated or inactivated, protein-based, viral vector, and nucleic acid vaccines. By mid-2021 three billion doses of COVID-19 vaccine have been administered around the world, mostly in high-income countries. COVID-19 vaccination provides hope for an end to the pandemic, if and only if there would be equal access and optimal uptake in all countries around the world.
引用
收藏
页码:111 / 116
页数:6
相关论文